EZH2 and prostate carcinoma: EZH2 is overexpressed in several types of cancer such as breast cancer, esophageal cancer, endometrial carcinoma, gastric cancer, nasopharyngeal carcinoma, prostate cancer, and thyroid carcinoma (Bachmann et al., 2006[2]; Fan et al., 2020[18]; Gan et al., 2018[20]; Krill et al., 2020[26]; Pellecchia et al., 2020[42]; Qiu et al., 2020[44]; Varambally et al., 2002[58]).